Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Chronic Myeloid Leukemia (CML)

 

Dasatinib Versus Imatinib for Chronic Phase Chronic Myeloid Leukemia
An Open Label, Randomized (2:1) Phase IIb Study of Dasatinib Versus Imatinib in Patients With Chronic Phase Chronic Myeloid Leukemia Who Have Not Achieved an Optimal Response to 3 Months of Therapy With 400 mg Imatinib

Investigator: Vivian G. Oehler, MD;   Conditions: Chronic Myeloid Leukemia;    Status: Recruiting;   Study ID: NCT01593254